# Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Source: https://onco.cc/trials/nct05379946/  
OnCo record `nct05379946` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Garsorasib and IN10018 in advanced solid tumours, run by InventisBio Co., Ltd, active and no longer recruiting.

## Summary

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05379946 by InventisBio Co., Ltd, with 92 participants enrolled, started 2022-10-12 and due to reach its primary completion in 2027-12-31. Interventions recorded: D-1553 and IN10018.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05379946
- Phase: 1/2
- Setting: A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Combination With IN10018 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation
- Sponsor: InventisBio Co., Ltd
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT05379946: https://clinicaltrials.gov/study/NCT05379946

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Garsorasib](https://onco.cc/drugs/garsorasib/), [IN10018](https://onco.cc/drugs/in10018/)
- companies: [InventisBio](https://onco.cc/companies/inventisbio/)

---
JSON: https://onco.cc/api/v1/entities/nct05379946.json